Management

Dan Bradbury is a Life Sciences Executive with over 40 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market, and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm based in La Jolla, CA.

Dan is the Chairman and Co-Founder of Equillium, Inc. (NASDAQ: EQ), a publicly traded biopharmaceutical company based in La Jolla, CA, focused on developing products to treat severe autoimmune and inflammatory disorders with high unmet medical need. He served as Executive Chairman until October 2025 and Chief Executive Officer until January 2020. He is the former President, Chief Executive Officer, and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes, and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals.

Dan serves on the board of directors of Castle Biosciences, Inc. (NASDAQ: CSTL), Equillium, Inc. (NASDAQ: EQ), Vivani Medical, Inc. (NASDAQ: VANI) and a number of private companies and philanthropic organizations.

Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from the University of West London in the United Kingdom.

View Bio as PDF
View CV as PDF

Bethany Heintz brings 30 years of experience supporting senior executives in the life sciences industry. She is the Chief Administrative Officer at BioBrit, LLC, where she leads operations, provides support to the companies and funds within the portfolio, and executes the firm’s strategic initiatives.

Bethany also serves as Chief of Staff at Equillium, Inc. (NASDAQ: EQ), a biopharmaceutical company focused on therapies for severe autoimmune and inflammatory disorders. In this role, she works closely with the Executive Leadership Team and Board of Directors to align priorities, support the company’s mission, and help achieve its corporate goals.